View in EDS HTML Full Text PDF Full Text

Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma.

Saved in:
Bibliographic Details
Title: Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Authors: Liang R; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Li X; Department of Radiation Oncology, Shenzhen Luohu People's Hospital, Shenzhen, China., Zhu M; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Lan F; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Fu F; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Lei L; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Zou T; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Ma L; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Chen P; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Luo L; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Jin J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China., Zhang J; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
Source: Frontiers in immunology [Front Immunol] 2026 May 25; Vol. 17, pp. 1766797. Date of Electronic Publication: 2026 May 25 (Print Publication: 2026).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42266699
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Liang+R%22">Liang R</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; Department of Radiation Oncology, Shenzhen Luohu People's Hospital, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Zhu+M%22">Zhu M</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Lan+F%22">Lan F</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Fu+F%22">Fu F</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Lei+L%22">Lei L</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Zou+T%22">Zou T</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Ma+L%22">Ma L</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Chen+P%22">Chen P</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Luo+L%22">Luo L</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Jin+J%22">Jin J</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.<br /><searchLink fieldCode="AU" term="%22Zhang+J%22">Zhang J</searchLink>; Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101560960%22">Frontiers in immunology</searchLink> [Front Immunol] 2026 May 25; Vol. 17, pp. 1766797. <i>Date of Electronic Publication: </i>2026 May 25 (<i>Print Publication: </i>2026).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101560960 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Internet <i>ISSN: </i>1664-3224 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2216643224%22">16643224 </searchLink><i>NLM ISO Abbreviation: </i>Front Immunol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42266699
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fimmu.2026.1766797
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1766797
    Titles:
      – TitleFull: Immunotherapy plus induction chemotherapy followed by radiotherapy alone or one cycle of concurrent chemotherapy with cisplatin vs induction chemotherapy followed by two cycles of concurrent chemotherapy with cisplatin in locoregionally advanced nasopharyngeal carcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Liang R
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Zhu M
      – PersonEntity:
          Name:
            NameFull: Lan F
      – PersonEntity:
          Name:
            NameFull: Fu F
      – PersonEntity:
          Name:
            NameFull: Lei L
      – PersonEntity:
          Name:
            NameFull: Zou T
      – PersonEntity:
          Name:
            NameFull: Ma L
      – PersonEntity:
          Name:
            NameFull: Chen P
      – PersonEntity:
          Name:
            NameFull: Luo L
      – PersonEntity:
          Name:
            NameFull: Jin J
      – PersonEntity:
          Name:
            NameFull: Zhang J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 25
              M: 05
              Text: 2026 May 25
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1664-3224
          Numbering:
            – Type: volume
              Value: 17
          Titles:
            – TitleFull: Frontiers in immunology
              Type: main
ResultId 1